Biotech IV Monitor

ROIV — Roivant Sciences Ltd.

$27.0B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Roivant Sciences Ltd., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$27.0B
Cash & investments$4.21B~22 quarters at last loss rate
Recent 8-K filings2latest 2026-11-09

No trial records on file for this company.

Cash position

Roivant Sciences Ltd. reported $4.21B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $192M; at that rate the cash would last about 22 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09
8-K Reg FD Disclosure — often a data announcement2026-10-21

Discussion

No messages yet. If you follow ROIV, you can start the conversation.
Track ROIV in real time
See live implied volatility for ROIV and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ROIV
Contact — questions or corrections about ROIV: dukeupt@gmail.com